Cargando…

Pilot Study: Assessing the Expression of Serum Lactate Dehydrogenase and Peripheral Leukocyte Ratios in Canine Oral Malignant Melanoma

SIMPLE SUMMARY: This study aimed to assess the expression of novel blood biomarkers in dogs with oral malignant melanoma, an aggressive and common oral cancer in dogs. The results of this pilot study suggest that the concentrations of lactate dehydrogenase, which can be easily measured with blood sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Ben, Blacklock, Kelly L. Bowlt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416752/
https://www.ncbi.nlm.nih.gov/pubmed/36006336
http://dx.doi.org/10.3390/vetsci9080421
Descripción
Sumario:SIMPLE SUMMARY: This study aimed to assess the expression of novel blood biomarkers in dogs with oral malignant melanoma, an aggressive and common oral cancer in dogs. The results of this pilot study suggest that the concentrations of lactate dehydrogenase, which can be easily measured with blood samples, are significantly higher in dogs with oral malignant melanoma. These blood biomarkers have been shown to be of prognostic value in human melanoma patients, meaning that they can act to predict the potential behaviour of the tumour. Therefore, research into our canine patients should be viewed as being potentially very valuable, as the discovery of easily measurable prognostic biomarkers could significantly further not only our understanding of the underlying physiology of melanoma itself, but also change the way veterinary surgeons investigate and treat the disease in the future. This study lays the foundations for further, more extensive investigation, into the topic. ABSTRACT: Measurement of blood biomarkers such as lactate dehydrogenase (LDH) and peripheral leukocyte ratios have been shown to be of prognostic value in human melanoma patients. Previous veterinary studies have demonstrated that changes in these values are detectable in multiple canine cancer patients. However, to the authors’ knowledge, no studies have yet demonstrated an increase in LDH in canine oral malignant melanoma patients, nor has the effect of metastasis on LDH levels been explored. This retrospective pilot study included 18 dogs, of which 10 were healthy controls, 5 OMM patients with metastasis and 3 without metastasis. Serum LDH was measured and pre-treatment peripheral leucocyte ratios were calculated. LDH was measurable within all patient groups and a statistically significant difference in LDH levels was detected between patients with OMM and healthy controls (p < 0.05); however, no significant difference was detected between patients with or without metastatic disease. This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker.